跳转至内容
Merck
所有图片(1)

文件

EMU055071

Sigma-Aldrich

MISSION® esiRNA

targeting mouse Anxa5

登录查看公司和协议定价
所有图片(1)

About This Item

分類程式碼代碼:
41105324
NACRES:
NA.51

描述

Powered by Eupheria Biotech

產品線

MISSION®

形狀

lyophilized powder

esiRNA cDNA 標靶序列

AACCTGTTGACATCCCGAAGCAATGCTCAGCGCCAGGAAATTGCTCAGGAGTTTAAGACTCTGTTTGGCAGGGACCTTGTGGATGACCTGAAGTCTGAACTGACTGGAAAGTTTGAGAAGTTAATTGTGGCTATGATGAAGCCCTCACGACTCTACGATGCCTACGAGCTGAAGCATGCTCTTAAGGGAGCTGGTACAGACGAGAAAGTATTGACCGAGATTATTGCTTCAAGGACACCTGAAGAACTCAGTGCCATAAAACAAGTTTATGAAGAAGAATATGGTTCCAACCTGGAAGATGATGTGGTGGGGGATACTTCAGGGTACTACCAGAGGATGTTGGTGGTCCTCCTTCAGGCGAATAGAGACCCTGATACTGCAATTGATGATGCTCAAGTTGAACTGGATGCTCAGGCATTGTTCCAGGCTGGAGAGCTGAAGTGGGGGACAGATGAAGAAAAATTCATCACCATCTTTGGGACA

Ensembl | 小鼠類登錄號

ENSMUSG00000027712

NCBI登錄號

NM_009673

運輸包裝

ambient

儲存溫度

−20°C

基因資訊

mouse ... ANXA5(11747) , Anxa5(11747)

一般說明

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

法律資訊

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

儲存類別代碼

10 - Combustible liquids

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Nahee Park et al.
Journal of toxicology and environmental health. Part A, 77(22-24), 1467-1476 (2014-10-25)
Auranofin is a lipophilic gold compound with anti-inflammatory and immunosuppressive properties. This compound also exerts antiproliferative effects in several human cancer cell lines. Although auranofin induces apoptosis in human cancer cells, the underlying mechanisms remain unclear. This study investigated auranofin-mediated
Jingjing Wang et al.
Oncology reports, 32(6), 2557-2563 (2014-10-18)
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma worldwide. Although patient outcomes have significantly improved to a greater than 40% cure rate by the combinatorial cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy, which is widely

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门